Researchers have identified a small molecule that may help treat people with epilepsy whose condition has become resistant to the benzodiazepine drugs usually used in managing seizures. The research, conducted in laboratory cells and rodents, was published in Cell Reports Medicine.
Uncontrolled epilepsy can lead to frequent and prolonged seizures lasting five minutes or more that can cause brain cell damage and even death. The condition affects an estimated 3.4 million people in the U.S. and millions more worldwide.
Epilepsy occurs when the intricate, delicate balance of signaling by neurons in the brain malfunctions, causing neurons to fire too much and trigger seizures. Benzodiazepines slow down the messages traveling between neurons.
“While seizures can frequently be controlled with medications, up to 30 percent of those with epilepsy develop drug resistance after a period of time,” says study co-first author.
The scientists were looking for targets in the brain that could restore normal signaling. They focused on a potassium chloride co-transporter called KCC2. In the normal brain, KCC2 helps pump chloride out of nerve cells, which helps brake neuronal overfiring.
“Previous research in both rodents and humans had shown that low KCC2 levels and activity in the brain is linked to drug-resistant and prolonged seizures,” explains a co-first author.
The collaborators screened more than one million compounds to identify a family of compounds that might be able to affect the activity of KCC2 in the brain.
The scientists tested one of the compounds in that family – Compound 350 – and observed that in combination with benzodiazepine, the Compound 350 reduced seizure activity in rodents with drug-resistant seizures.
“We also observed that mice treated with the benzodiazepine and Compound 350 had lower cell death in the brain than those treated only with the benzodiazepine,” said the author, adding that this was most likely because rodents treated with both drugs were not having as many seizures.
“The small molecules we have identified have the capacity to be developed as first-in-class drugs to alleviate drug-resistant epilepsies and neurodegenerative disorders,” says the uathor. “In collaboration with Ovid Therapeutics, these compounds are now under clinical development.”
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00049-6
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fdirect-activation-of&filter=22
Activating potassium-chloride co-transporter to treat epilepsy
- 380 views
- Added
Latest News
Defective myelin promotes A…
By newseditor
Posted 09 Jun
NAD+ metabolic enzyme's rol…
By newseditor
Posted 09 Jun
Viruses such as SARS-CoV-2…
By newseditor
Posted 09 Jun
A pair of brain regions pro…
By newseditor
Posted 09 Jun
How the gut microbiome resp…
By newseditor
Posted 08 Jun
Other Top Stories
Diet has rapid effects on sperm quality
Read more
Cognitive behavioral therapy for social anxiety can have a protecti…
Read more
Association of short or long sleep with pulmonary fibrosis
Read more
Cilia and centrioles
Read more
Recalling the past and imagining the future using memory engrams
Read more
Protocols
Hardwiring tissue-specific…
By newseditor
Posted 08 Jun
Using mass spectrometry ima…
By newseditor
Posted 07 Jun
Low-threshold, high-resolut…
By newseditor
Posted 05 Jun
Optical opening of the bloo…
By newseditor
Posted 04 Jun
Protocol to establish a gen…
By newseditor
Posted 03 Jun
Publications
Transcriptomic atlas and in…
By newseditor
Posted 09 Jun
Myelin dysfunction drives a…
By newseditor
Posted 09 Jun
Steroid receptor coactivato…
By newseditor
Posted 09 Jun
Taurine linked with healthy…
By newseditor
Posted 09 Jun
SARS-CoV-2 infection and vi…
By newseditor
Posted 09 Jun
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 10 Mar
ASCO-2020-GYNECOLOGIC CANCER
By newseditor
Posted 10 Mar